|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Depressive Disorder | |||||
| Parkinson Disease | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Depression | |||||
| 3 | More general conditions related to this trial | ||||
| Basal Ganglia Diseases | |||||
| Behavioral Symptoms | |||||
| Brain Diseases | |||||
| Central Nervous System Diseases | |||||
| Mental Disorders | |||||
| Mood Disorders | |||||
| Movement Disorders | |||||
| Nervous System Diseases | |||||
| Neurodegenerative Diseases | |||||
| Parkinsonian Disorders | |||||
| 4 | Interventions listed in this trial | ||||
| Atomoxetine | |||||
| Placebo | |||||
| 5 | More general drug interventions related to this trial | ||||
| Adrenergic Agents | |||||
| Adrenergic Uptake Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Neurotransmitter Uptake Inhibitors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Mental Health (NIMH) | |||||